1 |
Abbas H, Elyamany A, Salem M, et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35.
DOI
ScienceOn
|
2 |
Arends L, Hunink M, Stijnen T, et al (2008). Meta-analysis of summary survival curve data. Stat Med, 27, 4381-96.
DOI
|
3 |
Arkoob K, Al-Nsour M, Al-Nemry O, et al (2010). Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Health J, 16, 1032-8.
|
4 |
Azrif M, Ibrahim J, Aslan N, et al (2011). Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital. Asian Pac J Cancer Prev, 12, 157-62.
|
5 |
Camlibel B, Dine S (2005). A comparison of the outcomes of non-randomized chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer, 24, 363-72.
|
6 |
Chen D, Lai L, Duan C, et al (2014). Conservative surgery plus axillary radiotherapy vs modified radical mastectomy in patients with stage I breast cancer. Clin Breast Cancer, 14, 10-3.
DOI
|
7 |
Chen S, Huang L, Liu Y, et al (2013). The predictive and prognostic significance of pre- and post-treatment topoisomerase IIalpha in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. Eur J Surg Oncol, 39, 619-26.
DOI
|
8 |
Dear KB (1994). Iterative generalized least squares for metaanalysis of survival data at multiple times. Biometrics, 989-1002.
|
9 |
DerSimonian R, Kacker R (2007). Random-effects model for meta-analysis of clinical trials: an update. Contemporary Clinical Trials, 28, 105-14.
DOI
ScienceOn
|
10 |
Duman B, Afsar C, Gunaldi M, et al (2012). Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients. Asian Pac J Cancer Prev, 13, 4119-23.
DOI
|
11 |
Earl H, Hiller M, Dunn J, et al (2012). Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Br J Cancer, 107, 1257-67.
DOI
|
12 |
Guyot P, Ades A, Ouwens M, et al (2012). Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol, 12, 9.
DOI
|
13 |
Faradmal J, Kazemnejad A, Bakhshi R (2010). Comparing three adjuvant chemotherapy regimes after modified radical mastectomy in breast cancer patients using log-logistic model. J Semnan Univ Med Sci, 11, 279-86.
|
14 |
Gogia A, Raina V, Deo S, et al (2014). Inflammatory breast cancer: a single centre analysis. Asian Pac J Cancer Prev, 15, 3207-10.
DOI
|
15 |
Gupta D, Raina V, Rath G, et al (2011). Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: eight-year experience from single centre. Indian J Cancer, 48, 410-4.
DOI
|
16 |
Ismaili N, Elmajjaoui S, Lalya I, et al (2010). Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes, 3, 247.
|
17 |
Ismaili N, Mellas N, Masbah O, et al (2009). Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol, 4, 12.
DOI
ScienceOn
|
18 |
Ji M, Tang J, Zhao J (2012). Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracyclinebased neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biology Therapy, 13, 264-71.
DOI
|
19 |
Katalinic A, Pritzkuleit R , Waldmann A (2009). Recent trends in breast cancer incidence and mortality in Germany. Breast Care (Basel), 4, 75-80.
DOI
ScienceOn
|
20 |
Klein M (2005). Survival analysis: a self-learning text, Springer.
|
21 |
Phua C, Bustam A, Yusof M, et al (2012). Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. Asian Pac J Cancer Prev, 13, 4623-6.
DOI
|
22 |
Leo A, Desmedt C, Bartlett J, et al (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol, 12, 1134-42.
DOI
ScienceOn
|
23 |
Li L, Xu X, Zhao Y, et al (2009). Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat, 113, 231-7.
DOI
|
24 |
Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91.
DOI
|
25 |
Sharif F, Abshorshori N, Tahmasebi S, et al (2010). The effect of peer-led education on the life quality of mastectomy patients referred to breast cancer-clinics in Shiraz, Iran 2009. Health Qual Life Outcomes, 8, 74.
DOI
ScienceOn
|
26 |
Sharma B, Satyanarayan A, Kalwar N, et al (2013). Five year retrospective survival analysis of triple negative breast cancer in North-West India. Indian J Cancer, 50, 330-2.
DOI
|
27 |
Society AC (2007). Breast cancer facts & figures 2007-2008, American cancer society Atlanta.
|
28 |
Tokiniwa H, Horiguchi J, Takata D, et al (2012). Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer, 19, 309-14.
DOI
|
29 |
Wakamatsu S, Mitsuyama S, Nanba K, et al (2006). Adjuvant therapy for breast cancer in Kyushu. Breast Cancer, 13, 308-12.
DOI
|
30 |
Wang S, Shi Y, Yuan Z, et al (2012). Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxanebased regimens. Medical Oncol, 29, 547-53.
DOI
|
31 |
Wu H, Kang H, Liu Y, et al (2012). Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol, 138, 1449-62.
DOI
|
32 |
Xue C, Wang X, Peng R, et al (2012). Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci, 103, 1679-87.
DOI
|
33 |
Yao L, Liu Y, Li Z, et al (2011). HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann Oncol, 22, 1326-31.
DOI
|
34 |
Zare N, Doostfatemeh M, Rezaianzadeh A (2012). Modeling of breast cancer prognostic factors using a parametric loglogistic model in Fars province, Southern Iran. Asian Pac J Cancer Prev, 13, 1533-7.
DOI
ScienceOn
|
35 |
Zare N, Ghanbari S, Salehi A (2013). Effects of two chemotherapy regimens, anthracycline-based and CMF, on breast cancer disease free survival in the Eastern Mediterranean Region and Asia: a meta-analysis approach for survival curves. Asian Pac J Cancer Prev, 14, 2013-7.
DOI
|
36 |
Zare N, Haem E, Lankarani KB, et al (2013). Breast cancer risk factors in a defined population: weighted logistic regression approach for rare events. J Breast Cancer, 16, 214-9.
DOI
|
37 |
Zhang J, Liu Y (2008). HER2 over-expression and response to different chemotherapy regimens in breast cancer. J Zhejiang Univ Sci B, 9, 5-9.
DOI
ScienceOn
|